GHIC Announces the Launch of the Global Health Security Fund with $353M in Commitments

NEW YORK, NY – Global Health Investment Corporation (GHIC) launched Global Health Security Fund, L.P. (GHSF) with support from the U.S. Government’s Biomedical Advanced Research and Development Authority (BARDA) and a group of mission-aligned investors to accelerate the development of technologies and products that strengthen global health security. These investors include the Coalition for Epidemic Preparedness Innovations (CEPI), Flu Lab, Eli Lilly and Company, Meiji Seika Pharma Co., Ltd., The MITRE Corporation, and the Wisconsin Alumni Research Foundation (WARF). Funding was also committed to GHSF by GHIC’s Catalytic Health Investment Platform (CHIP), a partnership with the Government of Germany through its KfW Development Bank and the Federal Ministry of Economic Cooperation and Development.

GHSF invests in companies developing medical countermeasures and other technologies that have both impact and commercial market potential. GHSF’s portfolio includes companies developing innovative products and platforms to address critical gaps in global health preparedness and response, with a focus on vaccines, therapeutics, diagnostics, and enabling technologies to prevent and minimize the damage of public health emergencies.

“Global health security requires sustained investment, continued innovation, and strong collaboration across the public and private sectors,” said Labeeb Abboud, Chairman and CEO of GHIC. “By leveraging the commitment and contributions of our investors and partners, the Global Health Security Fund is accelerating transformational technologies to achieve our shared vision for a safer and healthier world.”

GHSF builds on GHIC’s experience at the intersection of global health and private capital, leveraging its network across government, industry, and the scientific community to identify and support high-impact technologies.

About Global Health Investment Corporation (GHIC)

A pioneer of investing in global health, GHIC has been supporting biomedical innovations for over a decade. GHIC's Global Health Investment Fund (GHIF) financed the development of products to combat public health challenges that disproportionately affect people living in low- and middle-income countries. In 2012, GHIC established a strategic partnership with Government of Germany through its Federal Ministry of Economic Cooperation and Development (BMZ) and KfW Development Bank to catalyze investment in the field of global health product development. In 2021, GHIC entered a venture investment partnership focused on global health security with the Biomedical Advanced Research and Development Authority (BARDA), Office of the Assistant Secretary for Preparedness & Response (ASPR), U.S. Department of Health and Human Services.

Notices and Disclaimers

Nothing contained in this release shall constitute an offer to sell, or a solicitation of an offer to purchase, any interest in GHSF or any other fund or investment vehicle managed or advised by GHIC or its affiliates. GHIC and its affiliates do not solicit or make investment advisory or other services available to the public or advisory clients other than privately offered funds. This release may contain forward-looking statements. Any such statements are based on current expectations, estimates, projections, and assumptions, and are not guarantees of future performance. Forward-looking statements involve risks, uncertainties, and assumptions that could cause actual results to differ materially from those expressed or implied by such statements.